PCM
SPRO icon

Prelude Capital Management’s Spero Therapeutics SPRO Stock Holding History

Prelude Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,726
Closed -$8K – 1894
2022
Q2 		$8K Buy
+10,726
New +$31.2K ﹤0.01% 1589
2020
Q4 		– Sell
-300
Closed -$3K – 1932
2020
Q3 		$3K Buy
300
+200
+200% +$2.37K ﹤0.01% 1639
2020
Q2 		$1K Sell
100
-600
-86% -$6.74K ﹤0.01% 1886
2020
Q1 		$6K Sell
700
-200
-22% -$1.76K ﹤0.01% 1214
2019
Q4 		$9K Buy
900
+200
+29% +$2.16K ﹤0.01% 1723
2019
Q3 		$7K Buy
700
+200
+40% +$2.11K ﹤0.01% 1533
2019
Q2 		$6K Buy
+500
New +$6.02K ﹤0.01% 1505

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Prelude Capital Management's SPRO Position: Q3 2022 in Review

Prelude Capital Management sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 10,726 shares — an estimated $8K sold.

Prelude Capital Management first reported a position in SPRO in Q2 2019 and held it in 7 quarters. The position peaked at $9K in Q4 2019. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • Prelude Capital Management reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 10,726 Spero Therapeutics shares in Q3 2022, an estimated $8K.
  • Prelude Capital Management first reported a position in Spero Therapeutics in Q2 2019 and held it in 7 quarters.
  • Prelude Capital Management's Spero Therapeutics position peaked at $9K in Q4 2019.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.